These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 17148970

  • 1. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.
    Cooper CL, Mills E, Angel JB.
    AIDS; 2007 Jan 02; 21(1):71-6. PubMed ID: 17148970
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
    Petoumenos K, Ringland C, Australian HIV Observational Database.
    HIV Med; 2005 May 02; 6(3):155-63. PubMed ID: 15876281
    [Abstract] [Full Text] [Related]

  • 3. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.
    AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069
    [Abstract] [Full Text] [Related]

  • 4. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
    Cooper CL, Mills E.
    Int J STD AIDS; 2007 Aug 12; 18(8):546-50. PubMed ID: 17686217
    [Abstract] [Full Text] [Related]

  • 5. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V.
    J Antimicrob Chemother; 2010 Mar 12; 65(3):543-7. PubMed ID: 20032006
    [Abstract] [Full Text] [Related]

  • 6. HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability.
    Shuhart MC, Sullivan DG, Bekele K, Harrington RD, Kitahata MM, Mathisen TL, Thomassen LV, Emerson SS, Gretch DR.
    J Infect Dis; 2006 May 01; 193(9):1211-8. PubMed ID: 16586356
    [Abstract] [Full Text] [Related]

  • 7. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, Tositti G, Colangeli V, Lichtner M, Monforte Ad, ICoNA Study Group.
    AIDS; 2007 Mar 12; 21(5):599-606. PubMed ID: 17314522
    [Abstract] [Full Text] [Related]

  • 8. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, Penco G, Gianelli E, Martinelli C, Carradori S, Quirino T, Rizzardini G, CISAI Study Group.
    Biomed Pharmacother; 2008 Jan 12; 62(1):16-20. PubMed ID: 17851026
    [Abstract] [Full Text] [Related]

  • 9. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
    Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U.
    AIDS; 2008 Jan 11; 22(2):203-10. PubMed ID: 18097222
    [Abstract] [Full Text] [Related]

  • 10. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Bani-Sadr F, Goderel I, Morand P, Payan C, Lunel F, Pol S, Perronne C, Carrat F, Cacoub P.
    AIDS; 2007 Jul 31; 21(12):1645-8. PubMed ID: 17630563
    [Abstract] [Full Text] [Related]

  • 11. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P, French National Agency for Research on AIDS, Viral Hepatitis-HC02-Ribavic Study Team.
    Clin Infect Dis; 2008 Mar 01; 46(5):768-74. PubMed ID: 18248298
    [Abstract] [Full Text] [Related]

  • 12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 01; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 13. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V, Tural C, EACS Executive Committee.
    HIV Med; 2008 Feb 01; 9(2):82-8. PubMed ID: 18257771
    [Abstract] [Full Text] [Related]

  • 14. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
    Winters MA, Chary A, Eison R, Asmuth D, Holodniy M.
    J Med Virol; 2010 May 01; 82(5):791-8. PubMed ID: 20336744
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A.
    HIV Med; 2007 Jul 01; 8(5):280-7. PubMed ID: 17561873
    [Abstract] [Full Text] [Related]

  • 16. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection.
    Vallet-Pichard A, Pol S.
    J Hepatol; 2006 Jul 01; 44(1 Suppl):S28-34. PubMed ID: 16343684
    [Abstract] [Full Text] [Related]

  • 17. Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals.
    Tornero C, Alberola J, Tamarit A, Navarro D.
    Clin Microbiol Infect; 2006 Jun 01; 12(6):555-60. PubMed ID: 16700705
    [Abstract] [Full Text] [Related]

  • 18. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.
    Zeitoun JD, Mallet V, Chaix ML, Viard JP, Blanche S, Pol S.
    J Clin Virol; 2007 Sep 01; 40(1):71-3. PubMed ID: 17658294
    [Abstract] [Full Text] [Related]

  • 19. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA.
    Antivir Ther; 2006 Sep 01; 11(7):839-46. PubMed ID: 17302246
    [Abstract] [Full Text] [Related]

  • 20. Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus.
    Endo T, Fujimoto K, Nishio M, Yamamoto S, Obara M, Sato N, Koike T.
    J Med Virol; 2009 Jun 01; 81(6):979-82. PubMed ID: 19382259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.